Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.37M | -9.53M | 10.36M | -16.29M | -15.84M |
| Total Depreciation and Amortization | 331.00K | 344.00K | 323.00K | 340.00K | 381.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.54M | -1.09M | -18.35M | 16.50M | 3.69M |
| Change in Net Operating Assets | -18.26M | -12.07M | 5.66M | -18.05M | -2.70M |
| Cash from Operations | -18.76M | -22.34M | -2.00M | -17.50M | -14.48M |
| Capital Expenditure | -19.00K | -556.00K | -95.00K | 0.00 | -401.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -19.00K | -556.00K | -95.00K | 0.00 | -401.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.49M | 37.26M | 82.90M | 0.00 | 47.36M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -1.55M | -47.03M | -285.00K | -- |
| Cash from Financing | 4.49M | 35.71M | 35.87M | -285.00K | 47.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.29M | 12.81M | 33.77M | -17.78M | 32.48M |